Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Marimastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 9/20 | 1.00 |
| ▸ | MMP2 known ✓ | P08253 | 8/20 | 1.00 |
| ▸ | MMP3 known ✓ | P08254 | 6/20 | 1.00 |
| ▸ | MMP9 known ✓ | P14780 | 5/20 | 1.00 |
| ▸ | MMP7 known ✓ | P09237 | 3/20 | 1.00 |
| ▸ | MMP12 known ✓ | P39900 | 1/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 13/20 | 1.00 |
| ▸ | MMP8 | P22894 | 6/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 1.00 |
| ▸ | MMP20 | O60882 | 1/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | MMP10 | P09238 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | MMP15 | P51511 | 1/20 | 1.00 |
| ▸ | MMP16 | P51512 | 1/20 | 1.00 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 1.00 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
| ▸ | MMP24 | Q9Y5R2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marimastat SCHEMBL31231856 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL134999 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL1821430 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8189167 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL34033 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL13253251 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL8193003 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL17799241 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL20793036 | 1.00 | ADAM17 (1.00) | ADAM17MMP1MMP2MMP3MMP8 | |
| Marimastat SCHEMBL7931107 | 0.99 | ADAM17 (0.97) | ADAM17MMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550978-B2 | Isolation and functional identification of cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | UNIVERSIDAD DE SALAMANCA (ES) | 2016-02-18 | — | — | US | disclosed |
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | UNIVERSIDAD DE SALAMANCA (ES) | 2016-02-18 | — | — | US | disclosed |
| WO-2014083229-A1 | USE OF METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF POLYCYSTIC LIVER DISEASES | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI (ES) | 2014-06-05 | — | — | WO | disclosed |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-03-13 | — | — | US | disclosed |
| US-20130295636-A1 | Isolation and Functional Identification of Cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130216608-A1 | Airway Administration of Angiogenesis Inhibitors | TRIFOILIUM APS (DK) | 2013-08-22 | — | — | US | disclosed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | MMP1 400/4885MMP2 254/4885MMP3 453/4885 |
| US-20160045463-A1 | USE OF METALLOPROTEASE INHIBITORS IN THE TREATMENT OF POLYCYSTIC LIVER DISEASES | PKD1, MMP3, PKD2 | MMP1 23/4885MMP2 37/4885MMP3 2/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | MMP1 400/4885MMP2 254/4885MMP3 453/4885 |
| US-20130216608-A1 | Airway Administration of Angiogenesis Inhibitors | VEGFA, SERPINB1, MMP1 | MMP1 3/4885MMP2 14/4885MMP3 104/4885 |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | PLOD3, MYOC, SLTM | MMP1 389/4885MMP2 803/4885MMP3 132/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | MMP1 740/4885MMP2 1672/4885MMP3 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.